Paraoxonases (PONs) are a family of lactonases with promiscuous enzyme activity that has been implicated in multiple diseases. PON2 is intracellularly located, is the most ubiquitously expressed PON, and has the highest lactonase activity of the PON family members. Whereas some single-nucleotide polymorphisms (SNPs) in PON1 have resulted in altered enzymatic activity in serum, to date the functional consequences of SNPs on PON2 function remain unknown. We hypothesized that a common PON2 SNP would result in impaired lactonase activity. Substitution of cysteine for serine at codon 311 in recombinant PON2 resulted in normal protein production and localization but altered glycosylation and decreased lactonase activity. Moreover, we screened 200 human lung samples for the PON2 Cys(311) variant and found that in vivo this mutation impaired lactonase activity. These data suggest that impaired lactonase activity may play a role in innate immunity, atherosclerosis, and other diseases associated with the PON2 311 SNP.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2790986 | PMC |
http://dx.doi.org/10.1074/jbc.M109.051706 | DOI Listing |
Int J Biol Macromol
December 2024
State Key Laboratory of Food Science and Resources, Jiangnan University, Wuxi, Jiangsu 214122, China. Electronic address:
Recently, how could microbial lactonase react to the mycotoxin zearalenone (ZEN) and its derivatives such as α-zearalenol (α-ZOL) is still unclear, resulting in limited applications. In this study, the interaction networks of residues near the β6-α6 region in lactonase from Monosporascus sp. GIB2 (ZENM) were analyzed.
View Article and Find Full Text PDFArch Pharm (Weinheim)
December 2024
NEUROFARBA Department, Pharmaceutical and Nutraceutical Section, University of Florence, Firenze, Italy.
Lactones, a diverse and abundant class of molecules found in nature, exhibit a wide range of bioactivities, including anti-inflammatory, anticancer, and antibacterial effects. Among them, acyl homoserine lactones (AHSLs) play a crucial role in quorum sensing, influencing bacterial pathogenicity and biofilm formation in Gram-negative bacteria. Paraoxonases (PONs), calcium-containing enzymes known for their lactonase activity, have been shown to hydrolyze AHSLs and reduce the biofilm formation of several pathogenic bacteria.
View Article and Find Full Text PDFMol Biol Rep
October 2024
NyBerMan Bioinformatics Europe, Paddenstoelenlaan 8, 3451 PZ Utrecht, Netherlands.
Background: Qurom quenching enzyme have an impact on treatment efficacy and prevent the recurrence of Helicobacter pylori biofilm-related infections, although it has not been thoroughly investigated in vitro and in silico. The current study aims to characterize the N-acyl homoserine lactonase, the quorum quenching AiiA protein of Bacillus licheniformis against H. pylori biofilm.
View Article and Find Full Text PDFmBio
December 2024
Instituto de Biología Molecular y Celular de Rosario, Consejo Nacional de Investigaciones Científicas y Tecnológicas, Universidad Nacional de Rosario, Rosario, Argentina.
Unlabelled: , a member of the Enterobacteriaceae family, is an opportunistic human pathogen and a frequent cause of urinary tract infections. Clinical isolates often exhibit resistance to multiple antibiotics, posing challenges for successful treatment. Understanding its pathogenic mechanisms is crucial for elucidating new potential targets to develop effective therapeutic interventions and manage infections.
View Article and Find Full Text PDFRMD Open
October 2024
Department of Medicine, Division of Rheumatology, University of California Los Angeles, David Geffen School of Medicine, Los Angeles, California, USA.
Objective: Paraoxonase-1 (PON1) is a high-density lipoprotein (HDL)-associated enzyme, that has been implicated as a biomarker of cardiovascular risk in patients with rheumatoid arthritis (RA). We aimed to investigate how different biologic therapies affect levels of PON1 and oxylipins.
Methods: 1213 adult patients with RA in the Comparative Effectiveness Registry to study Therapies for Arthritis and Inflammatory CoNditions cohort study with moderate-to-high disease activity (Clinical Disease Activity Index (CDAI) >10) who initiated a new biologic (tocilizumab (TCZ), n=296; abatacept, n=374; tumour necrosis factor inhibitors, n=427; rituximab, n=116) were followed prospectively with serum specimens analysed for PON1 activity by arylesterase (ARYL), lactonase (LAC) and PON assays at baseline and after 6 months of biologic therapy.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!